A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Public ClinicalTrials.gov record NCT04139304. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label Feasibility Study of Daratumumab With Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
Study identification
- NCT ID
- NCT04139304
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Early Phase 1
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Interventions
- Cyclophosphamide Drug
- Daratumumab Biological
- Doxorubicin Drug
- Doxorubicin Hydrochloride Drug
- Etoposide Drug
- Prednisone Drug
- Vincristine Drug
- Vincristine Sulfate Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 23, 2021
- Primary completion
- Jun 30, 2029
- Completion
- Jun 30, 2030
- Last update posted
- Jun 28, 2025
2021 – 2030
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Miami Miller School of Medicine | Miami | Florida | 33136 | Recruiting |
| University of Illinois at Chicago | Chicago | Illinois | 60612 | Recruiting |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | Maryland | 21231 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | Recruiting |
| University of North Carolina - Chapel Hill | Chapel Hill | North Carolina | 27514 | Recruiting |
| The Ohio State University | Columbus | Ohio | 43210 | Recruiting |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04139304, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 28, 2025 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04139304 live on ClinicalTrials.gov.